BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20007583)

  • 1. Expression of soluble vascular endothelial growth factor receptor-1 in human monocyte-derived mature dendritic cells contributes to their antiangiogenic property.
    Kishuku M; Nishioka Y; Abe S; Kishi J; Ogino H; Aono Y; Azuma M; Kinoshita K; Batmunkh R; Makino H; Ranjan P; Minakuchi K; Sone S
    J Immunol; 2009 Dec; 183(12):8176-85. PubMed ID: 20007583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic effect of soluble vascular endothelial growth factor receptor-1 in placental angiogenesis.
    Ahmad S; Ahmed A
    Endothelium; 2005; 12(1-2):89-95. PubMed ID: 16036320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen and selective estrogen receptor modulators regulate vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in human endometrial stromal cells.
    Okada H; Tsutsumi A; Imai M; Nakajima T; Yasuda K; Kanzaki H
    Fertil Steril; 2010 May; 93(8):2680-6. PubMed ID: 19828145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
    Ebos JM; Bocci G; Man S; Thorpe PE; Hicklin DJ; Zhou D; Jia X; Kerbel RS
    Mol Cancer Res; 2004 Jun; 2(6):315-26. PubMed ID: 15235107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A.
    Lamszus K; Ulbricht U; Matschke J; Brockmann MA; Fillbrandt R; Westphal M
    Clin Cancer Res; 2003 Apr; 9(4):1399-405. PubMed ID: 12684411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells in vitro: Comparative study with HUVEC.
    Jayasinghe C; Simiantonaki N; Michel-Schmidt R; Kirkpatrick CJ
    Int J Mol Med; 2009 Jan; 23(1):49-55. PubMed ID: 19082506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia.
    Stachon A; Aweimer A; Stachon T; Tannapfel A; Thoms S; Ubrig B; Köller M; Krieg M; Truss MC
    Growth Factors; 2009 Apr; 27(2):71-8. PubMed ID: 19199116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.
    Guo Y; Wang S; Hoot DR; Clinton SK
    J Nutr Biochem; 2007 Jun; 18(6):408-17. PubMed ID: 17142033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
    Mahendra G; Kumar S; Isayeva T; Mahasreshti PJ; Curiel DT; Stockardt CR; Grizzle WE; Alapati V; Singh R; Siegal GP; Meleth S; Ponnazhagan S
    Cancer Gene Ther; 2005 Jan; 12(1):26-34. PubMed ID: 15359287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular endothelial growth factor and its soluble receptor in benign and malignant ovarian tumors.
    Artini PG; Ruggiero M; Monteleone P; Carpi A; Cristello F; Cela V; Genazzani AR
    Biomed Pharmacother; 2008; 62(6):373-7. PubMed ID: 18037256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
    Joseph IB; Isaacs JT
    Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
    Ogawa T; Takayama K; Takakura N; Kitano S; Ueno H
    Cancer Gene Ther; 2002 Aug; 9(8):633-40. PubMed ID: 12136423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of soluble vascular endothelial growth factor receptor 1 secretion from human endothelial cells by tissue inhibitor of metalloproteinase 1.
    Bruegmann E; Gruemmer R; Neulen J; Motejlek K
    Mol Hum Reprod; 2009 Nov; 15(11):749-56. PubMed ID: 19584194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.